The results of a phase I trial show that recombinant human endostatin is safe and well tolerated by patients with refractory solid tumors. Furthermore, the antiangiogenesis agent conferred clinical benefit to 3 of 15 patients included in the trial.
The “unprecedented interest” in endostatin resulting from media reports led to a recruitment process that was “quite different from a typical phase I clinical trial,” Dr. Joseph P. Eder, Jr. of the Dana Farber Cancer Institute in Boston, and colleagues note.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!